If no timeframe is specified, information refers to Q1-3/2017

Q3/2017:

• Sales: €8.3 billion (+12%, +15% in constant currency)
• EBIT¹: €1,129 million (+5%, +9% in constant currency)
• Net income^2,3 (adjusted): €423 million (+11%, +14% in constant currency)
• Net income²: €396 million (+4%, +7% in constant currency)

Q1-3/2017:

• Sales: €25.2 billion (+16%, +16% in constant currency)
• EBIT¹: €3,522 million (+15%, +15% in constant currency)
• Net income^2,3 (adjusted): €1,339 million (+20%, +20% in constant currency)
• Net income²: €1,303 million (+17%, +17% in constant currency)

Stephan Sturm, CEO of Fresenius, said: “We can report another very good quarter, once again boosted by strong sales and earnings growth. The prospects for our businesses remain excellent. We are therefore confirming our guidance and are heading towards yet another record year. From this position of strength, we intend to swiftly close and integrate our strategically important acquisitions. Thus, we are expanding our range of high-quality, affordable healthcare products and services for the benefit of our patients and our company.“

¹ Before acquisition-related expenses
² Net income attributable to shareholders of Fresenius SE & Co. KGaA
³ Consistent with scope of original guidance: before acquisition-related expenses; before expenditures for further development of biosimilars business

For a detailed overview of adjustments, please see the reconciliation tables on page 15-16 in the pdf document.

2017 Group guidance confirmed

Fresenius confirms its guidance for 2017. Group sales are expected to increase by 15% to 17% in constant currency. Group net income^1,2,3 is expected to grow by 19% to 21% in constant currency.

Including the acquisition of Merck KGaA’s biosimilars business and pro forma the acquisition of Akorn, the net debt/EBITDA⁴ ratio is expected to be approximately 3.3 at the end of 2017.

16% sales growth in constant currency

Group sales increased by 16% (16% in constant currency) to €25,191 million (Q1-3/2016: €21,651 million). Organic sales growth was 6%⁵ while acquisitions contributed 10%. In Q3/2017, Group sales increased by 12% (15% in constant currency) to €8,297 million (Q3/2016: €7,433 million). Negative currency translation effects (-3%) were mainly related to the devaluation of the US dollar. Organic sales growth was 6% while acquisitions contributed 9%.

 

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA
² Before acquisition-related expenses of ~€50 m
³ Before expected expenditures for further development of biosimilars business of ~€60 m
⁴ Net debt and EBITDA at FY average exchange rates; before acquisition-related expenses of ~€50 m; excluding further potential acquisitions
⁵ Excluding effects of Fresenius Medical Care’s agreement with the United States Departments of Veterans Affairs and Justice (VA agreement)

For a detailed overview of adjustments, please see the reconciliation tables on page 15-16 in the pdf document.

 

Group sales by region:

 

20% adjusted net income^2,3 growth in constant currency

Group EBITDA⁴ increased by 16% (16% in constant currency) to €4,579 million (Q1-3/2016: €3,959 million). Group EBIT⁴ increased by 15% (15% in constant currency) to €3,522 million (Q1-3/2016: €3,058 million) with an EBIT margin⁴ of 14.0% (Q1-3/2016: 14.1%). In Q3/2017, Group EBIT⁴ increased by 5% (9% in constant currency) to €1,129 million (Q3/2016: €1,071 million) with an EBIT margin⁴ of 13.6% (Q3/2016: 14.4%).

Group net interest⁴ reached -€484 million (Q1-3/2016: -€433 million). The increase is mainly driven by the financing of the Quirónsalud acquisition.

 

¹ Including effects of VA agreement
² Net income attributable to shareholders of Fresenius SE & Co. KGaA
³ Consistent with scope of original guidance: before acquisition-related expenses; before expenditures for further development of biosimilars business
⁴ Before acquisition-related expenses

For a detailed overview of adjustments, please see the reconciliation tables on page 15-16 in the pdf document.

The Group tax rate¹ was 28.1% (Q1-3/2016: 28.2%). In Q3/2017, the Group tax rate¹ decreased to 27.4% (Q3/2016: 27.9%), mainly driven by a re-evaluation of estimated future tax payments at Fresenius Medical Care.

Noncontrolling interest increased to €854 million (Q1-3/2016: €768 million), of which 95% was attributable to the noncontrolling interest in Fresenius Medical Care.

Adjusted Group net income^2,3 increased by 20% (20% in constant currency) to €1,339 million (Q1-3/2016: €1,118 million). Adjusted earnings per share^2,3 increased by 19% (19% in constant currency) to €2.42 (Q1-3/2016: €2.04). In Q3/2017, adjusted Group net income^2,3 increased by 11% (14% in constant currency) to €423 million (Q3/2016: €382 million). Adjusted earnings per share^2,3 increased by 11% (14% in constant currency) to €0.77 (Q3/2016: €0.69).

Group net income before acquisition-related expenses^1,2 increased by 19% (19% in constant currency) to €1,329 million (Q1-3/2016: €1,118 million). Earnings per share^1,2 increased by 18% (18% in constant currency) to €2.40 (Q1-3/2016: €2.04). In Q3/2017, Group net income^1,2 increased by 8% (11% in constant currency) to €413 million (Q3/2016: €382 million). Earnings per share^1,2 increased by 8% (11% in constant currency) to €0.75 (Q3/2016: €0.69).

Group net income² increased by 17% (17% in constant currency) to €1,303 million (Q1-3/2016: €1,118 million). Earnings per share² increased by 15% (15% in constant currency) to €2.35 (Q1-3/2016: €2.04). In Q3/2017, Group net income² increased by 4% (7% in constant currency) to €396 million (Q3/2016: €382 million). Earnings per share² increased by 3% (6% in constant currency) to €0.71 (Q3/2016: €0.69).

 

¹ Before acquisition-related expenses
² Net income attributable to shareholders of Fresenius SE & Co. KGaA
³ Consistent with scope of original guidance: before acquisition-related expenses; before expenditures for further development of biosimilars business

For a detailed overview of adjustments, please see the reconciliation tables on page 15-16 in the pdf document.

Continued investment in growth

Spending on property, plant and equipment was €1,137 million (Q1-3/2016: €1,059 million), primarily for the modernization and expansion of dialysis clinics, production facilities as well as hospitals and day clinics. Total acquisition spending of €6,662 million (Q1-3/2016: €592 million) was mainly related to the acquisitions of Quirónsalud and Merck KGaA’s biosimilars business.

Strong operating cash flow

Operating cash flow increased by 24% to €2,821 million (Q1-3/2016: €2,273 million). The cash flow margin increased to 11.2% (Q1-3/2016: 10.5%). In Q3/2017, operating cash flow increased by 21% to €1,138 million (Q3/2016: €940 million), with a margin of 13.7% (Q3/2016: 12.6%).

Free cash flow before acquisitions and dividends increased by 41% to €1,705 million (Q1-3/2016: €1,206 million). Free cash flow after acquisitions and dividends was -€5,233 million (Q1-3/2016: €252 million).

Solid balance sheet structure

The Group’s total assets increased by 14% (20% in constant currency) to €53,097 million (Dec. 31, 2016: €46,697 million), mainly due to the acquisition of Quirónsalud. Current assets grew by 10% (16% in constant currency) to €12,870 million (Dec. 31, 2016: €11,744 million). Non-current assets increased by 15% (22% in constant currency) to €40,227 million (Dec. 31, 2016: € 34,953 million).

Total shareholders’ equity grew by 2% (10% in constant currency) to €21,167 million (Dec. 31, 2016: €20,849 million). The equity ratio was 39.9% (Dec. 31, 2016: 44.6%).

Group debt increased by 32% (37% in constant currency) to €19,496 million (Dec. 31, 2016: € 14,780 million), mainly driven by the acquisition financing of Quirónsalud. As of September 30, 2017, the net debt/EBITDA ratio was 2.97^1,2 (Dec. 31, 2016: 2.33¹; pro forma Quirónsalud 3.09¹).

 

¹ Net debt and EBITDA at LTM average exchange rates
² Before acquisition-related expenses

For a detailed overview of adjustments, please see the reconciliation tables on page 15-16 in the pdf document.

Increased number of employees
As of September 30, 2017, the number of employees increased by 17% to 271,676 (Dec. 31, 2016: 232,873).

Business Segments

Fresenius Medical Care

Fresenius Medical Care is the world's largest provider of products and services for individuals with chronic kidney failure. As of September 30, 2017, Fresenius Medical Care was treating 317,792 patients in 3,714 dialysis clinics. Along with its core business, the company seeks to expand the range of medical services in the field of care coordination.

• Solid Q3 despite impact from natural disasters in North America
• 8% constant currency sales growth in Q3
• 2017 outlook confirmed²

Sales increased by 10% (10% in constant currency, 7% organic) to €13,355 million (Q1-3/2016: €12,153 million). Acquisitions and the agreement with the United States Departments of Veterans Affairs and Justice (VA agreement) contributed 3% in total. In Q3/2017, sales increased by 3% (8% in constant currency, 6% organic) to €4,336 million (Q3/2016: €4,211 million).

Health Care Services sales (dialysis services and care coordination) increased by 11% (10% in constant currency) to €10,950 million (Q1-3/2016: €9,910 million). Product sales increased by 7% (7% in constant currency) to €2,404 million (Q1-3/2016: €2,244 million).

In North America, sales increased by 10% (10% in constant currency) to €9,715 million (Q1-3/2016: €8,828 million). Health Care Services sales grew by 10% (10% in constant currency) to €9,086 million (Q1-3/2016: €8,224 million). Product sales increased by 4% (4% in constant currency) to €629 million (Q1-3/2016: €604 million).

Sales outside North America increased by 9% (10% in constant currency) to €3,628 million (Q1-3/2016: €3,315 million). Health Care Services sales increased by 11% (11% in constant currency) to €1,864 million (Q1-3/2016: €1,686 million). Product sales increased by 8% (8% in constant currency) to €1,764 million (Q1-3/2016: €1,630 million).

¹ Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA
² Excluding effects of VA agreement and natural disaster costs

 

EBIT increased by 10% (10% in constant currency) to €1,843 million (Q1-3/2016: €1,679 million). The EBIT margin was 13.8% (Q1-3/2016: 13.8%). In Q3/2017, EBIT was on the prior-year level (increased by 4% in constant currency) at €608 million (Q3/2016: €611 million). Foreign currency effects, lower contributions from the vascular business, higher costs in the pharmacy services business and natural disaster costs in North America negatively impacted EBIT, while organic growth and lower research and development expenses contributed positively. The EBIT margin was 14.0% (Q3/2016: 14.5%).

Net income¹ increased by 13% (14% in constant currency) to €886 million (Q1-3/2016: €781 million). Consistent with the original scope of guidance, i.e. excluding the effects of the VA agreement and natural disaster costs, net income¹ increased by 8% in constant currency. In Q3/2017, net income¹ grew by 2% (6% in constant currency) to €309 million (Q3/2016: €304 million). Excluding the effects of the VA agreement and natural disaster costs, net income¹ increased by 5% (8% in constant currency).

Operating cash flow increased by 43% to €1,664 million (Q1-3/2016: €1,160 million). The cash flow margin increased to 12.5% (Q1-3/2016: 9.5%). In Q3/2017, operating cash flow increased by 56% to €612 million (Q3/2016: €393 million) with a cash flow margin of 14.1% (Q3/2016: 9.3%). The increase is primarily attributable to last year’s cash contribution to a pension plan in the United States as well as other working capital items.

Fresenius Medical Care confirms its outlook for 2017. The company expects sales to grow by 8% to 10%² in constant currency. Net income^1,3 is expected to increase by 7% to 9% in constant currency.

For further information, please see Fresenius Medical Care’s Investor News at www.freseniusmedicalcare.com.

¹ Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA
² Excluding effects of VA agreement
³ Excluding effects of VA agreement and natural disaster costs

Fresenius Kabi

Fresenius Kabi offers intravenously administered generic drugs, clinical nutrition and infusion therapies for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products.

• 7% organic sales growth in Q3; positive contributions from all regions
• 11% adjusted EBIT growth² in constant currency in Q3
• 2017 outlook confirmed

Sales increased by 7% (7% in constant currency, 7% organic) to €4,764 million (Q1-3/2016: €4,457 million). Acquisitions/divestitures had no meaningful impact on sales. In Q3/2017, sales increased by 3% (7% in constant currency, 7% organic) to €1,562 million (Q3/2016: €1,511 million). Negative currency translation effects (-4%) were mainly related to the devaluation of the US dollar and the Chinese yuan against the Euro.

Sales in Europe increased by 4% (5% organic) to €1,635 million (Q1-3/2016: €1,569 million). In Q3/2017, sales increased by 3% (4% organic) to €538 million (Q3/2016: €521 million).

Sales in North America increased by 7% (6% organic) to €1,736 million (Q1-3/2016: €1,628 million). In Q3/2017, sales increased by 1% (7% organic) to €549 million (Q3/2016: €542 million).

Sales in Asia-Pacific increased by 9% (11% organic) to €894 million (Q1-3/2016: €821 million). In Q3/2017, sales increased by 8% (12% organic) to €312 million (Q3/2016: €290 million).

Sales in Latin America/Africa increased by 14% (10% organic) to €499 million (Q1-3/2016: €439 million). In Q3/2017, sales increased by 3% (8% organic) to €163 million (Q3/2016: €158 million).

 

¹ Before acquisition-related expenses
² Consistent with scope of original guidance: before acquisition-related expenses; before expenditures for further development of biosimilars business
³ Net income attributable to shareholders of Fresenius SE & Co. KGaA

For a detailed overview of adjustments, please see the reconciliation tables on page 15-16 in the pdf document.

 

Adjusted EBIT¹ increased by 6% (7% in constant currency) to €919 million (Q1-3/2016: €863 million). The adjusted EBIT margin¹ was 19.3% (Q1-3/2016: 19.4%). In Q3/2017, adjusted EBIT¹ increased by 6% (11% in constant currency) to €297 million (Q3/2016: €281 million), despite expenses related to hurricane Maria on Puerto Rico. The adjusted EBIT margin¹ increased to 19.0% (Q3/2016: 18.6%).

EBIT² increased by 5% (6% in constant currency) to €905 million (Q1-3/2016: €863 million). The EBIT margin² was 19.0% (Q1-3/2016: 19.4%). In Q3/2017, EBIT² increased by 1% (6% in constant currency) to €283 million (Q3/2016: €281 million). Given the €14 million expenditure for the further development of the biosimilars business, the EBIT margin² decreased to 18.1% (Q3/2016: 18.6%).

Adjusted net income^1,3 increased by 13% (14% in constant currency) to €554 million (Q1-3/2016: €491 million). In Q3/2017, adjusted net income^1,3 increased by 13% (19% in constant currency) to €175 million (Q3/2016: €155 million).

While operating cash flow reached a very strong €640 million, it could not match the exceptional prior-year figure (Q1-3/2016: €661 million). The same applied to the strong margin of 13.4% (Q1-3/2016: 14.8%). In Q3/2017, operating cash flow reached a healthy €245 million (Q3/2016: €322 million) despite a cash prepayment for the biosimilars business and adverse currency translation effects. The cash flow margin was 15.7% (Q3/2016: 21.3%). Excluding the prepayment, operating cash flow was €290 with a margin of 18.6%.

Fresenius Kabi confirms its outlook for 2017 and expects 5% to 7% organic sales growth and EBIT growth in constant currency of 6% to 8%^4,5.

 

¹ Consistent with scope of original guidance: before acquisition-related expenses; before expenditures for further development of biosimilars business
² Before acquisition-related expenses
³ Net income attributable to shareholders of Fresenius SE & Co. KGaA
⁴ Before acquisition-related expenses of ~€50 m
⁵ Before expected expenditures for further development of biosimilars business of ~€60 m

For a detailed overview of adjustments, please see the reconciliation tables on page 15-16 in the pdf document.

Fresenius Helios

Fresenius Helios is Europe's leading private hospital operator. The company comprises Helios Kliniken in Germany and Quirónsalud in Spain. Helios Kliniken operates 111 hospitals, thereof 88 acute care clinics and 23 post-acute care clinics, and treats more than 5.2 million patients annually. Quirónsalud operates 44 hospitals, 44 outpatient centers and around 300 occupational risk prevention centers, and treats approximately 9.7 million patients per year.

 

• 47% sales growth (4% excluding Quirónsalud) in Q3
• 33% EBIT increase (9% excluding Quirónsalud) in Q3
• 2017 outlook confirmed

Fresenius Helios increased sales by 47% (4% organic) to €6,422 million (Q1-3/2016: €4,382 million). Acquisitions, mainly Quirónsalud, increased sales by 43%. In Q3/2017, sales increased by 47% (4% organic) to €2,166 million (Q3/2016: €1,470 million).

Sales of Helios Kliniken² increased by 4% (4% organic) to €4,562 million (Q1-3/2016: €4,382 million). In Q3/2017, sales increased by 4% (4% organic) to €1,524 million (Q3/2016: €1,470 million). Quirónsalud has been consolidated since February 1, 2017 and generated sales of €1,860 million (thereof €642 million in Q3/2017).

Fresenius Helios grew EBIT by 52% to €769 million (Q1-3/2016: €507 million). The EBIT margin increased to 12.0% (Q1-3/2016: 11.6%). In Q3/2017, EBIT increased by 33% to €232 million (Q3/2016: €175 million). The EBIT margin decreased to 10.7% (Q3/2016: 11.9%) due to the anticipated lower contribution of Quirónsalud during the summer months.

EBIT of Helios Kliniken² increased by 8% to €549 million (Q1-3/2016: €507 million) with a margin of 12.0% (Q1-3/2016: 11.6%). In Q3/2017, EBIT of Helios Kliniken² increased by 9% to €190 million (Q3/2016: €175 million) with a margin of 12.5% (Q3/2016: 11.9%). EBIT of Quirónsalud was €220 million (thereof €42 million in Q3/2017) with a margin of 11.8% (Q3/2017: 6.5%).

Fresenius Helios increased net income¹ by 31% to €526 million (Q1-3/2016: €402 million). In Q3/2017, net income¹ increased by 9% to €153 million (Q3/2016: €140 million).

Operating cash flow increased by 28% to €560 million (Q1-3/2016: €437 million) driven by the first-time consolidation of Quirónsalud. The margin was 8.7% (Q1-3/2016: 10.0%).

Fresenius Helios confirms its outlook for 2017 and projects organic sales growth of 3% to 5%² and sales of ~€8.6 billion (thereof Quirónsalud ~€2.5 billion³). EBIT is expected to increase to €1,020 to €1,070 million (thereof Quirónsalud €300 to 320 million³).

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA
² Helios Kliniken Germany, excluding Quirónsalud
³ Quirónsalud consolidated for 11 months

Fresenius Vamed

Fresenius Vamed manages projects and provides services for hospitals and other health care facilities worldwide. The portfolio ranges along the entire value chain: from project development, planning, and turnkey construction, via maintenance and technical management, to total operational management.

• 9% sales growth in service business in Q3
• Project business with strong order intake of €285 million in Q3
• 2017 outlook confirmed

Sales increased by 1% (1% organic) to €748 million (Q1-3/2016: €740 million). Sales in the project business decreased by 7% to €301 million (Q1-3/2016: €325 million). Sales in the service business grew by 8% to €447 million (Q1-3/2016: €415 million). In Q3/2017, sales remained stable at €267 million (Q3/2016: €268 million).

EBIT increased by 3% to €32 million (Q1-3/2016: €31 million). The EBIT margin increased to 4.3% (Q1-3/2016: 4.2%). In Q3/2017, EBIT of €15 million (margin 5.6%) remained unchanged from previous year’s quarter.

Net income¹ remained stable at €21 million (Q1-3/2016: €21 million). In Q3/2017, net income¹ remained unchanged at €10 million (Q3/2016: €10 million).

Order intake reached a strong €697 million (Q1-3/2016: €674 million). In Q3/2017 order intake increased by 36% to €285 million. As of September 30, 2017, order backlog grew to an all-time high of €2,345 million (December 31, 2016: €1,961 million).

Fresenius Vamed confirms its outlook for 2017 and expects both organic sales growth and EBIT growth in the range of 5% to 10%.

¹ Net income attributable to shareholders of VAMED AG

 

 

Conference Call

As part of the publication of the results for the first nine months of 2017, a conference call will be held on November 2, 2017 at 2 p.m. CET (9 a.m. EDT). All investors are cordially invited to follow the conference call in a live broadcast over the Internet at www.fresenius.com/media-calendar. Following the call, a replay will be available on our website.

For additional information on the performance indicators, please refer to our website www.fresenius.com/alternative-performance-measures.

 

 

Fresenius laid the cornerstone today for a new office building in Bad Homburg, part of the company’s headquarters expansion, at a festive ceremony attended by employees along with political and business representatives.

The building at company headquarters on Else-Kröner-Strasse is a response to the steadily increasing number of Fresenius employees. When completed in 2019, its approximately 21,500 square meters (231,000 square feet) of floor space will house some 600 modern office workplaces, conference rooms, an additional staff canteen and a parking garage.

With its “L” form, the five-story structure was designed to fit into the overall architectural concept alongside the two existing headquarters buildings, but with new interpretations of some key architectural elements. For example, the façade will include translucent panels in the distinct design colors of the four Fresenius business segments. Access to all areas of the building will be through an 800-square-meter atrium crowned by a foil-cushion roof, with all three headquarters buildings joining on to a new outdoor common area where employees can enjoy their breaks on nice days.

Stephan Sturm, CEO of Fresenius, pointed in his speech to the contribution that modern office concepts can make to optimizing cooperation among colleagues. “The cornerstone we are laying today is for a new building – but also for even better cooperation between our employees. If we want to continue growing, we will need good cooperation. We must share ideas, and learn from each other. Growth also requires flexibility, and for this reason we are creating more spaces that are modern and open-concept, which will facilitate communications and can be modified in response to changing needs.”

Mayor Alexander Hetjes cited the important role Fresenius plays in his city: “Fresenius represents the modern face of Bad Homburg as a competence center for healthcare. From its base here the company is not just one of the biggest employers in the Rhine-Main region, but is active worldwide. Fresenius, through its many activities, also helps shape life in our city. The headquarters is now undergoing a major expansion, and Bad Homburg wishes the company, and all the employees who will work in this modern building, great success and a good future in our city.”

Designed by the Wiesbaden firm BGF+ Architekten, the new building is being erected on a former parking lot and part of the land previously occupied by a high-bay warehouse. After five months of renovation and rebuilding completed in August, the modernized warehouse now takes up less space but has 60 percent more capacity thanks to the installation of new shelving technology systems.

A new five-story parking garage with space for 681 vehicles that also opened last month is another component of the expansion project, in which Fresenius is investing about €70 million. The company currently employs about 3,400 people in Bad Homburg, and an additional 300 in the nearby town of Oberursel.

The amended 2013 Credit Agreement streamlines Fresenius’ financing structure by replacing the existing senior secured facilities with unsecured facilities. Concurrently, the guarantor structure was aligned, with Fresenius SE & Co KGaA now being sole guarantor. The Credit Agreement has an aggregate amount of approximately €3.8 billion and consists of revolving facilities and term loans with maturities in 2021 and 2022. The transaction was well received by investors and substantially oversubscribed. On the basis of the unsecured structure and consistent with the corporate credit rating of Fresenius, S&P has raised the rating of the Fresenius bonds to BBB- from BB+. 

The amended 2013 Credit Agreement streamlines Fresenius’ financing structure by replacing the existing senior secured facilities with unsecured facilities. Concurrently, the guarantor structure was aligned, with Fresenius SE & Co KGaA now being sole guarantor. The Credit Agreement has an aggregate amount of approximately €3.8 billion and consists of revolving facilities and term loans with maturities in 2021 and 2022. The transaction was well received by investors and substantially oversubscribed. On the basis of the unsecured structure and consistent with the corporate credit rating of Fresenius, S&P has raised the rating of the Fresenius bonds to BBB- from BB+.

If no timeframe is specified, information refers to H1/2017

Q2/2017:

• Sales: €8.5 billion (+18%, +17% in constant currency)
• EBIT¹: €1,177 million (+14%, +13% in constant currency)
• Net income^1,2: €459 million (+21%, +21% in constant currency)

H1/2017:

• Sales €16.9 billion (+19%, +17% in constant currency)
• EBIT¹: €2,393 million (+20%, +19% in constant currency)
• Net income^1,2: €916 million (+24%, +23% in constant currency)

Stephan Sturm, CEO of Fresenius, said: “We were able to sustain our strong momentum also in the second quarter. Strong increases in sales and earnings have put us well on track to reach our full-year targets. We are very pleased with the business development of Quirónsalud while its integration into Fresenius is proceeding according to plan. A focus in the second half will be to close the acquisitions announced by Fresenius Kabi. Those will put our business on an even broader foundation for future growth.”

 

^{1 Before special items2 Net income attributable to shareholders of Fresenius SE & Co. KGaA}

 

2017 Group guidance confirmed

Fresenius confirms its guidance for 2017. Group sales are expected to increase by 15% to 17% in constant currency. Group net income^1,2,3 is expected to grow by 19% to 21% in constant currency.

Pro forma the acquisitions of Akorn and Merck KGaA’s biosimilars business, the net debt/EBITDA⁴ ratio is expected to be approximately 3.3 at the end of 2017.

 

17% sales growth in constant currency

Group sales increased by 19% (17% in constant currency) to €16,894 million (H1/2016: €14,218 million). Organic sales growth was 6%⁵. Positive currency translation effects (2%) were mainly related to the appreciation of the U.S. dollar against the Euro. Acquisitions and the agreement with the United States Departments of Veterans Affairs and Justice at Fresenius Medical Care (“VA agreement”) contributed 11%. In Q2/2017, Group sales increased by 18% (17% in constant currency) to €8,532 million (Q2/2016: €7,203 million). Organic sales growth was 5%. Acquisitions contributed 12% while divestitures had no meaningful impact on sales.

 

^{1 Before transaction costs of ~€50 million for the acquisitions of Akorn, Inc. and Merck KGaA’s biosimilars business2 Before expected expenditures for the further development of Merck KGaA’s biosimilars business of ~€50 million (expected closing Q3/17)3 Net income attributable to shareholders of Fresenius SE & Co. KGaA4 Calculated at expected FY average exchange rates for both net debt and EBITDA; before transaction costs of ~€50 million; excluding further potential acquisitions5 Excluding effects of VA agreement}For a detailed overview of special items please see the reconciliation tables on page 15 in the PDF document.

Group sales by region:

 

23% net income² growth in constant currency

Group EBITDA³ increased by 20% (18% in constant currency) to €3,098 million (H1/2016: €2,586 million). Group EBIT³ increased by 20% (19% in constant currency) to €2,393 million (H1/2016: €1,987 million). The EBIT margin³ increased to 14.2% (H1/2016: 14.0%). In Q2/2017, Group EBIT³ increased by 14% (13% in constant currency) to €1,177 million (Q2/2016: €1,028 million), with an EBIT margin³ of 13.8% (Q2/2016: 14.3%).

Group net interest reached -€326 million³ (H1/2016: -€291 million), mainly due to the financing of the Quirónsalud acquisition.

The Group tax rate increased to 28.5%³ (H1/2016: 28.3%), mainly driven by the higher proportion of U.S. pre-tax income, primarily due to the VA agreement. In Q2/2017, the Group tax rate was 27.9%3 (Q2/2016: 28.2%).

¹ Including effects of VA agreement^{2 Net income attributable to shareholders of Fresenius SE & Co. KGaA; before special items3 Before special items}For a detailed overview of special items please see the reconciliation tables on page 15 in the PDF document.

 

Noncontrolling interest increased to €562 million (H1/2016: €480 million), of which 96% was attributable to the noncontrolling interest in Fresenius Medical Care.

Group net income¹ increased by 24% (23% in constant currency) to €916 million (H1/2016: €736 million). The VA agreement increased net income¹ growth by 2%-points. Earnings per share¹ increased by 22% (21% in constant currency) to €1.65 (H1/2016: €1.35). In Q2/2017, Group net income¹ increased by 21% (21% in constant currency) to €459 million (Q2/2016: €378 million). Earnings per share¹ increased by 19% (19% in constant currency) to €0.82 (Q2/2016: €0.70).

 

^{1 Net income attributable to shareholders of Fresenius SE & Co. KGaA; before special items}For a detailed overview of special items please see the reconciliation tables on page 15 in the PDF document.

 

Continued investment in growth

Spending on property, plant and equipment was €709 million (H1/2016: €674 million), primarily for the modernization and expansion of dialysis clinics, production facilities as well as hospitals and day clinics. Total acquisition spending of €6,421 million (H1/2016: €505 million) was mainly related to the acquisition of Quirónsalud.

 

Strong operating cash flow

Operating cash flow increased by 26% to €1,683 million (H1/2016: €1,333 million), mainly driven by the excellent development at Fresenius Medical Care and Fresenius Kabi. The cash flow margin increased to 10.0% (H1/2016: 9.4%). Operating cash flow in Q2/2017 increased by 21% to €1,207 million (Q2/2016: €997 million), with a margin of 14.1% (Q2/2016: 13.8%). As expected, the operating cash flow of Fresenius Medical Care improved considerably in Q2/2017.

Free cash flow before acquisitions and dividends increased by 54% to €998 million (H1/2016: €649 million). Free cash flow after acquisitions and dividends was -€5,645 million
(H1/2016: -€207 million).

 

Solid balance sheet structure

The Group’s total assets increased by 13% (18% in constant currency) to €52,897 million (Dec. 31, 2016: €46,697 million), mainly due to the acquisition of Quirónsalud. Current assets grew by 9% (14% in constant currency) to €12,799 million (Dec. 31, 2016: €11,744 million). Non-current assets increased by 15% (19% in constant currency) to €40,098 million (Dec. 31, 2016: € 34,953 million).

Total shareholders’ equity grew by 1% (6% in constant currency) to €21,020 million (Dec. 31, 2016: €20,849 million). The equity ratio was 39.7% (Dec. 31, 2016: 44.6%).

Group debt increased by 35% (39% in constant currency) to €19,910 million (Dec. 31, 2016: € 14,780 million), mainly driven by the acquisition financing of Quirónsalud. As of June 30, 2017, the net debt/EBITDA ratio was 3.00¹ (Dec. 31, 2016: 2.33¹; pro forma Quirónsalud 3.09¹).

¹ Net debt and EBITDA at LTM average exchange rates; before special itemsFor a detailed overview of special items please see the reconciliation tables on page 15 in the PDF document.

 

Business Segments

Fresenius Medical Care

Fresenius Medical Care is the world's largest provider of products and services for individuals with chronic kidney failure. As of June 30, 2017, Fresenius Medical Care was treating 315,305 patients in 3,690 dialysis clinics. Along with its core business, the company seeks to expand the range of medical services in the field of care coordination.

• 9% sales growth in constant currency in Q2
• 46% operating cash flow growth in Q2
• 2017 outlook confirmed

Sales increased by 14% (11% in constant currency, 7% organic) to €9,019 million (H1/2016: €7,942 million). Acquisitions/divestitures and the VA agreement contributed 4% in total. In Q2/2017, sales increased by 11% (9% in constant currency, 6% organic) to €4,471 million (Q2/2016: €4,026 million).

Health Care Services sales (dialysis services and care coordination) increased by 15% (11% in constant currency) to €7,418 million (H1/2016: €6,472 million). Product sales increased by 9% (7% in constant currency) to €1,601 million (H1/2016: €1,470 million).

In North America, sales increased by 14% to €6,600 million (H1/2016: €5,778 million). Health Care Services sales grew by 15% to €6,182 million (H1/2016: €5,383 million). Product sales increased by 6% to €418 million (H1/2016: €395 million).

Sales outside North America increased by 12% (10% in constant currency) to €2,410 million (H1/2016: €2,156 million). Health Care Services sales increased by 14% (11% in constant currency) to €1,236 million (H1/2016: €1,089 million). Product sales increased by 10% (8% in constant currency) to €1,174 million (H1/2016: €1,068 million).

EBIT increased by 16% (13% in constant currency) to €1,235 million (H1/2016: €1,068 million). The EBIT margin was 13.7% (H1/2016: 13.5%). Excluding the VA agreement EBIT increased by 7% (5% in constant currency). In Q2/2017, EBIT increased by 2% (stable in constant currency) to €584 million (Q2/2016: €571 million). The EBIT margin was 13.0% (Q2/2016: 14.2%).

Net income¹ increased by 21% (19% in constant currency) to €577 million (H1/2016: €477 million). Excluding the VA agreement net income1 increased by 10% (8% in constant currency). In Q2/2017, net income¹ grew by 2% (stable in constant currency) to €269 million (Q2/2016: €264 million).

Operating cash flow increased by 37% to €1,052 million (H1/2016: €767 million). The cash flow margin increased to 11.7% (H1/2016: 9.7%). In Q2/2017, operating cash flow increased by 46% to €882 million (Q2/2016: €604 million) with a cash flow margin of 19.7% (Q2/2016: 15.0%).

Fresenius Medical Care confirms its outlook for 2017. The company expects sales to grow by 8% to 10%² in constant currency. Net income^1,2 is expected to increase by 7% to 9% in constant currency.

¹ Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA^{2 Excluding effects of VA agreement}

For further information, please see Fresenius Medical Care’s Investor News at www.freseniusmedicalcare.com.

 

Fresenius Kabi

Fresenius Kabi offers intravenously administered generic drugs, clinical nutrition and infusion therapies for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products.

• 7% organic sales growth in Q2; positive contributions from all regions
• 9% constant currency EBIT growth in Q2
• 2017 outlook confirmed

Sales increased by 9% (7% in constant currency, 7% organic) to €3,202 million (H1/2016: €2,946 million). Acquisitions/divestitures had no meaningful impact on sales. In Q2/2017, sales increased by 8% (7% in constant currency and organic) to €1,598 million (Q2/2016: €1,476 million).

Sales in Europe increased by 5% (6% organic) to €1,097 million (H1/2016: €1,048 million). Currency translation effects had no meaningful impact. In Q2/2017, sales increased by 3% (4% organic) to €553 million (Q2/2016: €536 million).

Sales in North America increased by 9% (6% organic) to €1,187 million (H1/2016: €1,086 million). In Q2/2017, sales increased by 11% (9% organic) to €568 million (Q2/2016: €510 million).

Sales in Asia-Pacific increased by 10% (10% organic) to €582 million (H1/2016: €531 million). In Q2/2017, sales increased by 9% (10% organic) to €302 million (Q2/2016: €277 million).

Sales in Latin America/Africa increased by 20% (11% organic) to €336 million (H1/2016: €281 million), mainly due to inflation-driven price increases. In Q2/2017, sales increased by 14% (8% organic) to €175 million (Q2/2016: €153 million).

EBIT¹ increased by 7% (6% in constant currency) to €622 million (H1/2016: €582 million). The EBIT margin¹ was 19.4% (H1/2016: 19.8%). In Q2/2017, EBIT¹ increased by 11% (9% in constant currency) to €309 million (Q2/2016: €279 million). The EBIT margin¹ increased to 19.3% (Q2/2016: 18.9%).

Net income² increased by 13% (11% in constant currency) to €379 million (H1/2016: €336 million). In Q2/2017, net income² increased by 15% (13% in constant currency) to €188 million (Q2/2016: €163 million).

Operating cash flow increased by 17% to €395 million (H1/2016: €339 million) driven by strong operating results and improved net working capital. The margin increased to 12.3% (H1/2016: 11.5%). In Q2/2017, operating cash flow was €203 million (Q2/2016: €212 million). The cash flow margin was 12.7% (Q2/2016: 14.4%).

Fresenius Kabi confirms its outlook for 2017 and expects 5% to 7% organic sales growth and EBIT growth in constant currency of 6% to 8%^3,4.

^{1 Before special items2 Net income attributable to shareholders of Fresenius SE & Co. KGaA; before special items3 Before transaction costs of ~€50 million for the acquisitions of Akorn, Inc. and Merck KGaA’s biosimilars business4 Before expected expenditures for the further development of Merck KGaA’s biosimilars business of ~€50 million (expected closing Q3/17)}For a detailed overview of special items please see the reconciliation tables on page 15 in the PDF document.

 

Fresenius Helios

Fresenius Helios is Europe's leading private hospital operator. The company comprises HELIOS Kliniken in Germany and Quirónsalud in Spain. HELIOS Kliniken operates 112 hospitals, thereof 88 acute care clinics and 24 post-acute care clinics, and treats more than 5.2 million patients annually. Quirónsalud operates 44 hospitals, 44 outpatient centers and around 300 occupational risk prevention centers, and treats approximately 9.7 million patiens per year.

• 52% sales growth (2% excluding Quirónsalud) in Q2
• 63% EBIT increase (3% excluding Quirónsalud) in Q2
• 2017 outlook confirmed

Sales increased by 46% (4% organic) to €4,256 million (H1/2016: €2,912 million). Acquisitions, mainly Quirónsalud, increased sales by 42%. In Q2/2017, sales increased by 52% (2% organic) to €2,238 million (Q2/2016: €1,477 million).

Sales of HELIOS Kliniken² increased by 4% (4% organic) to €3,038 million (H1/2016: €2,912 million). In Q2/2017, sales increased by 2% (2% organic) to €1,510 million (Q2/2016: €1,477 million). Quirónsalud is consolidated since February 1, 2017 and generated sales of €1,218 million (thereof €728 million in Q2/2017).

EBIT grew by 62% to €537 million (H1/2016: €332 million). The EBIT margin increased to 12.6% (H1/2016: 11.4%). In Q2/2017, EBIT increased by 63% to €282 million (Q2/2016: €173 million). The EBIT margin increased to 12.6% (Q2/2016: 11.7%).

EBIT of HELIOS Kliniken² increased by 8% to €359 million with a margin of 11.8% (H1/2016: 11.4%). In Q2/2017, EBIT increased by 3% to €178 million (Q2/2016: €173 million). EBIT of Quirónsalud was €178 million (thereof €104 million in Q2/2017) with a margin of 14.6%.

Net income¹ increased by 42% to €373 million (H1/2016: €262 million). In Q2/2017, net income¹ increased by 39% to €192 million (Q2/2016: €138 million).

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA^{2 HELIOS Kliniken Germany, excluding Quirónsalud}

Operating cash flow increased by 32% to €304 million (H1/2016: €230 million) driven by the first-time consolidation of Quirónsalud and good operating results. The margin was 7.1% (H1/2016: 7.9%).

Fresenius Helios confirms its outlook for 2017 and projects organic sales growth of 3% to 5%¹ and sales of ~€8.6 billion (thereof Quirónsalud: ~€2.5 billion²). EBIT is expected to increase to €1,020 to €1,070 million (thereof Quirónsalud: €300 to 320 million²).

¹ HELIOS Kliniken Germany, excluding Quirónsalud^{2 Quirónsalud consolidated for 11 months}

 

Fresenius Vamed

Fresenius Vamed manages projects and provides services for hospitals and other health care facilities worldwide. The portfolio ranges along the entire value chain: from project development, planning, and turnkey construction, via maintenance and technical management, to total operational management.

• 2% sales growth in Q2 driven by service business
• Project business with strong order intake of €412 million in H1
• 2017 outlook confirmed

Sales increased by 2% (2% organic) to €481 million (H1/2016: €472 million). Sales in the project business decreased by 6% to €184 million (H1/2016: €195 million). Sales in the service business grew by 7% to €297 million (H1/2016: €277 million). In Q2/2017, sales increased by 2% (1% organic) to €258 million (Q2/2016: €254 million).

EBIT increased by 6% to €17 million (H1/2016: €16 million). The EBIT margin increased to 3.5% (H1/2016: 3.4%). In Q2/2017, EBIT increased by 22% to €11 million (Q2/2016: €9 million) with an EBIT margin of 4.3%.

Net income¹ remained unchanged at €11 million. In Q2/2017, net income¹ increased by 17% to €7 million (Q2/2016: €6 million).

Order intake reached a strong €412 million, but could not quite match the previous year’s excellent level (H1/2016: €465 million). As of June 30, 2017, order backlog grew to an all-time high of €2,188 million (December 31, 2016: €1,961 million).

Fresenius Vamed confirms its outlook for 2017 and expects both organic sales growth and EBIT growth in the range of 5% to 10%.

¹ Net income attributable to shareholders of VAMED AG

 

Conference Call

As part of the publication of the results for the first half of 2017, a conference call will be held on August 1, 2017 at 2 p.m. CEDT (8 a.m. EDT). All investors are cordially invited to follow the conference call in a live broadcast over the Internet at www.fresenius.com/investors. Following the call, a replay will be available on our website.

For additional information on the performance indicators, please refer to our website www.fresenius.com/alternative-performance-measures.

 

If no timeframe is specified, information refers to H1/2017

Q2/2017:

• Sales: €8.5 billion (+18%, +17% in constant currency)
• EBIT¹: €1,177 million (+14%, +13% in constant currency)
• Net income^1,2: €459 million (+21%, +21% in constant currency)

H1/2017:

• Sales: €16.9 billion (+19%, +17% in constant currency)
• EBIT¹: €2,393 million (+20%, +19% in constant currency)
• Net income^1,2: €916 million (+24%, +23% in constant currency)

Stephan Sturm, CEO of Fresenius, said: “We were able to sustain our strong momentum also in the second quarter. Strong increases in sales and earnings have put us well on track to reach our full-year targets. We are very pleased with the business development of Quirónsalud while its integration into Fresenius is proceeding according to plan. A focus in the second half will be to close the acquisitions announced by Fresenius Kabi. Those will put our business on an even broader foundation for future growth.”

 

¹ Before special items
² Net income attributable to shareholders of Fresenius SE & Co. KGaA

2017 Group guidance confirmed

Fresenius confirms its guidance for 2017. Group sales are expected to increase by 15% to 17% in constant currency. Group net income^1,2,3 is expected to grow by 19% to 21% in constant currency.

Pro forma the acquisitions of Akorn and Merck KGaA’s biosimilars business, the net debt/EBITDA⁴ ratio is expected to be approximately 3.3 at the end of 2017.

17% sales growth in constant currency

Group sales increased by 19% (17% in constant currency) to €16,894 million (H1/2016: €14,218 million). Organic sales growth was 6%⁵. Positive currency translation effects (2%) were mainly related to the appreciation of the U.S. dollar against the Euro. Acquisitions and the agreement with the United States Departments of Veterans Affairs and Justice at Fresenius Medical Care (“VA agreement”) contributed 11%. In Q2/2017, Group sales increased by 18% (17% in constant currency) to €8,532 million (Q2/2016: €7,203 million). Organic sales growth was 5%. Acquisitions contributed 12% while divestitures had no meaningful impact on sales.

¹ Before transaction costs of ~€50 million for the acquisitions of Akorn, Inc. and Merck KGaA’s biosimilars business
² Before expected expenditures for the further development of Merck KGaA’s biosimilars business of ~€50 million (expected closing Q3/17)
³ Net income attributable to shareholders of Fresenius SE & Co. KGaA
⁴ Calculated at expected FY average exchange rates for both net debt and EBITDA; before transaction costs of ~€50 million; excluding further potential acquisitions
⁵ Excluding effects of VA agreement
For a detailed overview of special items please see the reconciliation tables on page 15 in the PDF document.

Group sales by region:

23% net income² growth in constant currency

Group EBITDA³ increased by 20% (18% in constant currency) to €3,098 million (H1/2016: €2,586 million). Group EBIT³ increased by 20% (19% in constant currency) to €2,393 million (H1/2016: €1,987 million). The EBIT margin³ increased to 14.2% (H1/2016: 14.0%). In Q2/2017, Group EBIT³ increased by 14% (13% in constant currency) to €1,177 million (Q2/2016: €1,028 million), with an EBIT margin³ of 13.8% (Q2/2016: 14.3%).

Group net interest reached -€326 million³ (H1/2016: -€291 million), mainly due to the financing of the Quirónsalud acquisition.

The Group tax rate increased to 28.5%³ (H1/2016: 28.3%), mainly driven by the higher proportion of U.S. pre-tax income, primarily due to the VA agreement. In Q2/2017, the Group tax rate was 27.9%3 (Q2/2016: 28.2%).

¹ Including effects of VA agreement
² Net income attributable to shareholders of Fresenius SE & Co. KGaA; before special items
³ Before special items
For a detailed overview of special items please see the reconciliation tables on page 15 in the PDF document.

Noncontrolling interest increased to €562 million (H1/2016: €480 million), of which 96% was attributable to the noncontrolling interest in Fresenius Medical Care.

Group net income¹ increased by 24% (23% in constant currency) to €916 million (H1/2016: €736 million). The VA agreement increased net income¹ growth by 2%-points. Earnings per share¹ increased by 22% (21% in constant currency) to €1.65 (H1/2016: €1.35). In Q2/2017, Group net income¹ increased by 21% (21% in constant currency) to €459 million (Q2/2016: €378 million). Earnings per share¹ increased by 19% (19% in constant currency) to €0.82 (Q2/2016: €0.70).

 

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA; before special items
For a detailed overview of special items please see the reconciliation tables on page 15 in the PDF document.

Continued investment in growth

Spending on property, plant and equipment was €709 million (H1/2016: €674 million), primarily for the modernization and expansion of dialysis clinics, production facilities as well as hospitals and day clinics. Total acquisition spending of €6,421 million (H1/2016: €505 million) was mainly related to the acquisition of Quirónsalud.

Strong operating cash flow

Operating cash flow increased by 26% to €1,683 million (H1/2016: €1,333 million), mainly driven by the excellent development at Fresenius Medical Care and Fresenius Kabi. The cash flow margin increased to 10.0% (H1/2016: 9.4%). Operating cash flow in Q2/2017 increased by 21% to €1,207 million (Q2/2016: €997 million), with a margin of 14.1% (Q2/2016: 13.8%). As expected, the operating cash flow of Fresenius Medical Care improved considerably in Q2/2017.

Free cash flow before acquisitions and dividends increased by 54% to €998 million (H1/2016: €649 million). Free cash flow after acquisitions and dividends was -€5,645 million
(H1/2016: -€207 million).

Solid balance sheet structure

The Group’s total assets increased by 13% (18% in constant currency) to €52,897 million (Dec. 31, 2016: €46,697 million), mainly due to the acquisition of Quirónsalud. Current assets grew by 9% (14% in constant currency) to €12,799 million (Dec. 31, 2016: €11,744 million). Non-current assets increased by 15% (19% in constant currency) to €40,098 million (Dec. 31, 2016: € 34,953 million).

Total shareholders’ equity grew by 1% (6% in constant currency) to €21,020 million (Dec. 31, 2016: €20,849 million). The equity ratio was 39.7% (Dec. 31, 2016: 44.6%).

Group debt increased by 35% (39% in constant currency) to €19,910 million (Dec. 31, 2016: € 14,780 million), mainly driven by the acquisition financing of Quirónsalud. As of June 30, 2017, the net debt/EBITDA ratio was 3.00¹ (Dec. 31, 2016: 2.33¹; pro forma Quirónsalud 3.09¹).

¹ Net debt and EBITDA at LTM average exchange rates; before special items
For a detailed overview of special items please see the reconciliation tables on page 15 in the PDF document.

Business Segments

Fresenius Medical Care

Fresenius Medical Care is the world's largest provider of products and services for individuals with chronic kidney failure. As of June 30, 2017, Fresenius Medical Care was treating 315,305 patients in 3,690 dialysis clinics. Along with its core business, the company seeks to expand the range of medical services in the field of care coordination.

• 9% sales growth in constant currency in Q2
• 46% operating cash flow growth in Q2
• 2017 outlook confirmed

Sales increased by 14% (11% in constant currency, 7% organic) to €9,019 million (H1/2016: €7,942 million). Acquisitions/divestitures and the VA agreement contributed 4% in total. In Q2/2017, sales increased by 11% (9% in constant currency, 6% organic) to €4,471 million (Q2/2016: €4,026 million).

Health Care Services sales (dialysis services and care coordination) increased by 15% (11% in constant currency) to €7,418 million (H1/2016: €6,472 million). Product sales increased by 9% (7% in constant currency) to €1,601 million (H1/2016: €1,470 million).

In North America, sales increased by 14% to €6,600 million (H1/2016: €5,778 million). Health Care Services sales grew by 15% to €6,182 million (H1/2016: €5,383 million). Product sales increased by 6% to €418 million (H1/2016: €395 million).

Sales outside North America increased by 12% (10% in constant currency) to €2,410 million (H1/2016: €2,156 million). Health Care Services sales increased by 14% (11% in constant currency) to €1,236 million (H1/2016: €1,089 million). Product sales increased by 10% (8% in constant currency) to €1,174 million (H1/2016: €1,068 million).

EBIT increased by 16% (13% in constant currency) to €1,235 million (H1/2016: €1,068 million). The EBIT margin was 13.7% (H1/2016: 13.5%). Excluding the VA agreement EBIT increased by 7% (5% in constant currency). In Q2/2017, EBIT increased by 2% (stable in constant currency) to €584 million (Q2/2016: €571 million). The EBIT margin was 13.0% (Q2/2016: 14.2%).

Net income¹ increased by 21% (19% in constant currency) to €577 million (H1/2016: €477 million). Excluding the VA agreement net income1 increased by 10% (8% in constant currency). In Q2/2017, net income¹ grew by 2% (stable in constant currency) to €269 million (Q2/2016: €264 million).

Operating cash flow increased by 37% to €1,052 million (H1/2016: €767 million). The cash flow margin increased to 11.7% (H1/2016: 9.7%). In Q2/2017, operating cash flow increased by 46% to €882 million (Q2/2016: €604 million) with a cash flow margin of 19.7% (Q2/2016: 15.0%).

Fresenius Medical Care confirms its outlook for 2017. The company expects sales to grow by 8% to 10%² in constant currency. Net income^1,2 is expected to increase by 7% to 9% in constant currency.

¹ Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA
² Excluding effects of VA agreement

For further information, please see Fresenius Medical Care’s Investor News at www.freseniusmedicalcare.com.

Fresenius Kabi

Fresenius Kabi offers intravenously administered generic drugs, clinical nutrition and infusion therapies for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products.

• 7% organic sales growth in Q2; positive contributions from all regions
• 9% constant currency EBIT growth in Q2
• 2017 outlook confirmed

Sales increased by 9% (7% in constant currency, 7% organic) to €3,202 million (H1/2016: €2,946 million). Acquisitions/divestitures had no meaningful impact on sales. In Q2/2017, sales increased by 8% (7% in constant currency and organic) to €1,598 million (Q2/2016: €1,476 million).

Sales in Europe increased by 5% (6% organic) to €1,097 million (H1/2016: €1,048 million). Currency translation effects had no meaningful impact. In Q2/2017, sales increased by 3% (4% organic) to €553 million (Q2/2016: €536 million).

Sales in North America increased by 9% (6% organic) to €1,187 million (H1/2016: €1,086 million). In Q2/2017, sales increased by 11% (9% organic) to €568 million (Q2/2016: €510 million).

Sales in Asia-Pacific increased by 10% (10% organic) to €582 million (H1/2016: €531 million). In Q2/2017, sales increased by 9% (10% organic) to €302 million (Q2/2016: €277 million).

Sales in Latin America/Africa increased by 20% (11% organic) to €336 million (H1/2016: €281 million), mainly due to inflation-driven price increases. In Q2/2017, sales increased by 14% (8% organic) to €175 million (Q2/2016: €153 million).

EBIT¹ increased by 7% (6% in constant currency) to €622 million (H1/2016: €582 million). The EBIT margin¹ was 19.4% (H1/2016: 19.8%). In Q2/2017, EBIT¹ increased by 11% (9% in constant currency) to €309 million (Q2/2016: €279 million). The EBIT margin¹ increased to 19.3% (Q2/2016: 18.9%).

Net income² increased by 13% (11% in constant currency) to €379 million (H1/2016: €336 million). In Q2/2017, net income² increased by 15% (13% in constant currency) to €188 million (Q2/2016: €163 million).

Operating cash flow increased by 17% to €395 million (H1/2016: €339 million) driven by strong operating results and improved net working capital. The margin increased to 12.3% (H1/2016: 11.5%). In Q2/2017, operating cash flow was €203 million (Q2/2016: €212 million). The cash flow margin was 12.7% (Q2/2016: 14.4%).

Fresenius Kabi confirms its outlook for 2017 and expects 5% to 7% organic sales growth and EBIT growth in constant currency of 6% to 8%^3,4.

 

¹ Before special items
² Net income attributable to shareholders of Fresenius SE & Co. KGaA; before special items
³ Before transaction costs of ~€50 million for the acquisitions of Akorn, Inc. and Merck KGaA’s biosimilars business
⁴ Before expected expenditures for the further development of Merck KGaA’s biosimilars business of ~€50 million (expected closing Q3/17)
For a detailed overview of special items please see the reconciliation tables on page 15 in the PDF document.

Fresenius Helios

Fresenius Helios is Europe's leading private hospital operator. The company comprises HELIOS Kliniken in Germany and Quirónsalud in Spain. HELIOS Kliniken operates 112 hospitals, thereof 88 acute care clinics and 24 post-acute care clinics, and treats more than 5.2 million patients annually. Quirónsalud operates 44 hospitals, 44 outpatient centers and around 300 occupational risk prevention centers, and treats approximately 9.7 million patiens per year.

• 52% sales growth (2% excluding Quirónsalud) in Q2
• 63% EBIT increase (3% excluding Quirónsalud) in Q2
• 2017 outlook confirmed

Sales increased by 46% (4% organic) to €4,256 million (H1/2016: €2,912 million). Acquisitions, mainly Quirónsalud, increased sales by 42%. In Q2/2017, sales increased by 52% (2% organic) to €2,238 million (Q2/2016: €1,477 million).

Sales of HELIOS Kliniken² increased by 4% (4% organic) to €3,038 million (H1/2016: €2,912 million). In Q2/2017, sales increased by 2% (2% organic) to €1,510 million (Q2/2016: €1,477 million). Quirónsalud is consolidated since February 1, 2017 and generated sales of €1,218 million (thereof €728 million in Q2/2017).

EBIT grew by 62% to €537 million (H1/2016: €332 million). The EBIT margin increased to 12.6% (H1/2016: 11.4%). In Q2/2017, EBIT increased by 63% to €282 million (Q2/2016: €173 million). The EBIT margin increased to 12.6% (Q2/2016: 11.7%).

EBIT of HELIOS Kliniken² increased by 8% to €359 million with a margin of 11.8% (H1/2016: 11.4%). In Q2/2017, EBIT increased by 3% to €178 million (Q2/2016: €173 million). EBIT of Quirónsalud was €178 million (thereof €104 million in Q2/2017) with a margin of 14.6%.

Net income¹ increased by 42% to €373 million (H1/2016: €262 million). In Q2/2017, net income¹ increased by 39% to €192 million (Q2/2016: €138 million).

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA
² HELIOS Kliniken Germany, excluding Quirónsalud

Operating cash flow increased by 32% to €304 million (H1/2016: €230 million) driven by the first-time consolidation of Quirónsalud and good operating results. The margin was 7.1% (H1/2016: 7.9%).

Fresenius Helios confirms its outlook for 2017 and projects organic sales growth of 3% to 5%¹ and sales of ~€8.6 billion (thereof Quirónsalud: ~€2.5 billion²). EBIT is expected to increase to €1,020 to €1,070 million (thereof Quirónsalud: €300 to 320 million²).

¹ HELIOS Kliniken Germany, excluding Quirónsalud
² Quirónsalud consolidated for 11 months

Fresenius Vamed

Fresenius Vamed manages projects and provides services for hospitals and other health care facilities worldwide. The portfolio ranges along the entire value chain: from project development, planning, and turnkey construction, via maintenance and technical management, to total operational management.

• 2% sales growth in Q2 driven by service business
• Project business with strong order intake of €412 million in H1
• 2017 outlook confirmed

Sales increased by 2% (2% organic) to €481 million (H1/2016: €472 million). Sales in the project business decreased by 6% to €184 million (H1/2016: €195 million). Sales in the service business grew by 7% to €297 million (H1/2016: €277 million). In Q2/2017, sales increased by 2% (1% organic) to €258 million (Q2/2016: €254 million).

EBIT increased by 6% to €17 million (H1/2016: €16 million). The EBIT margin increased to 3.5% (H1/2016: 3.4%). In Q2/2017, EBIT increased by 22% to €11 million (Q2/2016: €9 million) with an EBIT margin of 4.3%.

Net income¹ remained unchanged at €11 million. In Q2/2017, net income¹ increased by 17% to €7 million (Q2/2016: €6 million).

Order intake reached a strong €412 million, but could not quite match the previous year’s excellent level (H1/2016: €465 million). As of June 30, 2017, order backlog grew to an all-time high of €2,188 million (December 31, 2016: €1,961 million).

Fresenius Vamed confirms its outlook for 2017 and expects both organic sales growth and EBIT growth in the range of 5% to 10%.

¹ Net income attributable to shareholders of VAMED AG

Conference Call

As part of the publication of the results for the first half of 2017, a conference call will be held on August 1, 2017 at 2 p.m. CEDT (8 a.m. EDT). All investors are cordially invited to follow the conference call in a live broadcast over the Internet at www.fresenius.com/media-calendar. Following the call, a replay will be available on our website.

For additional information on the performance indicators, please refer to our website www.fresenius.com/alternative-performance-measures.

 

 

 

 

 

 

 

 

 

 

The Supervisory Board of Fresenius Management SE has unanimously appointed Rachel Empey (41) as Chief Financial Officer of Fresenius, as of August 1, 2017. In this position she will succeed Stephan Sturm (54), who has continued to serve as CFO since his appointment as Chief Executive Officer of Fresenius last year.

Rachel Empey has been Chief Financial and Strategy Officer of Telefónica Deutschland Holding AG (“Telefónica Deutschland”) since 2011. Telefónica Deutschland is listed on the Frankfurt Stock Exchange and, with a market capitalization of more than €12 billion, is a leading TecDAX constituent. Before joining the Management Board of Telefónica Deutschland, Rachel Empey held a number of key international finance and controlling positions in the Telefónica group. She started her career as an auditor at Ernst & Young and business analyst at Lucent Technologies. Rachel Empey is British, a Chartered Accountant and holds an MA (Hons) in Mathematical Sciences from the University of Oxford.

Dr. Gerd Krick, Chairman of Fresenius Management SE’s Supervisory Board, said: “We are pleased to welcome a true financial expert and highly experienced manager as our new CFO. Among all the excellent candidates for this position, Rachel Empey impressed us with her exceptional technical expertise, sound strategic thinking and successful track record. She is a great addition to our proven management team.”

Stephan Sturm said: “I am very much looking forward to working with Rachel Empey. She is going to be the perfect fit for our Management Board. Along with first-rate qualifications and skills, wide-ranging experience and an engaging personality, she will bring new insights to Fresenius from another dynamic and innovative industry.”

Rachel Empey said: “I am very excited to be joining Fresenius and taking up this tremendous professional opportunity. Fresenius has a very strong position in the healthcare industry. I look forward to contributing to the company’s continued growth and consistent success as Chief Financial Officer.”

 

The Supervisory Board of Fresenius Management SE has unanimously appointed Rachel Empey (41) as Chief Financial Officer of Fresenius, as of August 1, 2017. In this position she will succeed Stephan Sturm (54), who has continued to serve as CFO since his appointment as Chief Executive Officer of Fresenius last year.

Rachel Empey has been Chief Financial and Strategy Officer of Telefónica Deutschland Holding AG (“Telefónica Deutschland”) since 2011. Telefónica Deutschland is listed on the Frankfurt Stock Exchange and, with a market capitalization of more than €12 billion, is a leading TecDAX constituent. Before joining the Management Board of Telefónica Deutschland, Rachel Empey held a number of key international finance and controlling positions in the Telefónica group. She started her career as an auditor at Ernst & Young and business analyst at Lucent Technologies. Rachel Empey is British, a Chartered Accountant and holds an MA (Hons) in Mathematical Sciences from the University of Oxford.

Dr. Gerd Krick, Chairman of Fresenius Management SE’s Supervisory Board, said: “We are pleased to welcome a true financial expert and highly experienced manager as our new CFO. Among all the excellent candidates for this position, Rachel Empey impressed us with her exceptional technical expertise, sound strategic thinking and successful track record. She is a great addition to our proven management team.”

Stephan Sturm said: “I am very much looking forward to working with Rachel Empey. She is going to be the perfect fit for our Management Board. Along with first-rate qualifications and skills, wide-ranging experience and an engaging personality, she will bring new insights to Fresenius from another dynamic and innovative industry.”

Rachel Empey said: “I am very excited to be joining Fresenius and taking up this tremendous professional opportunity. Fresenius has a very strong position in the healthcare industry. I look forward to contributing to the company’s continued growth and consistent success as Chief Financial Officer.”

 

 

 

Fresenius was presented yesterday with the Corporate Finance Award for the company's acquisition of Quirónsalud, Spain’s largest private hospital operator. The award is given annually by the major German business daily Börsen-Zeitung for transactions judged to be outstanding in both strategical and financial terms. Fresenius won in the Large Caps category, which groups major companies. With the Quirónsalud acquisition, the Börsen-Zeitung said, “Fresenius succeeded in making a quantum leap in the hospital business."

Fresenius was presented yesterday with the Corporate Finance Award for the company's acquisition of Quirónsalud, Spain’s largest private hospital operator. The award is given annually by the major German business daily Börsen-Zeitung for transactions judged to be outstanding in both strategical and financial terms. Fresenius won in the Large Caps category, which groups major companies. With the Quirónsalud acquisition, the Börsen-Zeitung said, “Fresenius succeeded in making a quantum leap in the hospital business."